‘Government Patent Use’: A Legal Approach To Reducing Drug Spending

National Health Spending In 2014: Faster Growth Driven By Coverage Expansion And Prescription Drug Spending

(2016) Anne B. Martin et al.   HEALTH AFFAIRS

Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States

(2015) Soumitri Barua et al.   ANNALS OF INTERNAL MEDICINE

Do March-In Rights Ensure Access to Medical Products Arising From Federally Funded Research? A Qualitative Study

(2015) CAROLYN L. TREASURE et al.   MILBANK QUARTERLY

The $2.6 Billion Pill — Methodologic and Policy Considerations

(2015) Jerry Avorn   NEW ENGLAND JOURNAL OF MEDICINE

Is widespread screening for hepatitis C justified?

(2015) R. L. Koretz et al.   BMJ-British Medical Journal

Is widespread screening for hepatitis C justified?

(2015) R. L. Koretz et al.   BMJ-British Medical Journal

Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010

(2014) Maxine M. Denniston et al.   ANNALS OF INTERNAL MEDICINE

Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries

(2014) A. Hill et al.   CLINICAL INFECTIOUS DISEASES

New Expensive Treatments for Hepatitis C Infection

(2014) Troyen Brennan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

(2013) Eric Lawitz et al.   NEW ENGLAND JOURNAL OF MEDICINE